^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AlloNK (GCC4001)

    i
    Associations
    News

    Trials

    Company:
    GC Biopharma
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) (NCT05883449)
    Phase 2
    Affimed GmbH
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/10/2023
    Primary completion :
    04/30/2026
    Completion :
    11/30/2027
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)